Health Trials

Pneumococcal Infectious Disease

3

Review clinical trials related to Pneumococcal Infectious Disease. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical Trial of PCV24 in Infants Aged 2-23 Months

A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase Ib clinical trial.

Participants needed: 180
Trial details
Phase: Phase 1Age: 42-23Biological sex: AllType: InterventionalSponsor: Sinovac Life Sciences Co., Ltd.Updated: Jan 28, 2026Locations: 2
Eligibility criteria

Healthy infants who are aged 2 months (42-89 days), 7-11 months, 12-23 months; [+3]

Received any pneumococcal vaccine prior to enrollment; [+17]

Read more
Status: Recruiting

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.

Participants needed: 3,080
Trial details
Phase: Phase 3Age: 6-5Biological sex: AllType: InterventionalSponsor: Sinovac Life Sciences Co., Ltd.Updated: Jan 28, 2026Locations: 1
Eligibility criteria

Healthy infants or children who are aged 2 months (at least 6 weeks), 7-11 month... [+3]

Received any pneumococcal vaccine prior to enrollment; [+17]

Read more
Status: Recruiting

Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years

A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase 2 clinical trial.

Participants needed: 420
Trial details
Phase: Phase 2Age: 42-5Biological sex: AllType: InterventionalSponsor: Sinovac Life Sciences Co., Ltd.Updated: Dec 24, 2025Locations: 3
Eligibility criteria

Healthy infants who are aged 2 months (42-89 days), 7-11 months, 12-23 months, a... [+3]

Received any pneumococcal vaccine prior to enrollment; [+17]

Read more